219 related articles for article (PubMed ID: 33879075)
1. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
Jakobsen JÅ; Quattrocchi CC; Müller FHH; Outteryck O; Alcázar A; Reith W; Fraga P; Panebianco V; Sampedro A; Pietura R
BMC Med Imaging; 2021 Apr; 21(1):74. PubMed ID: 33879075
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study.
Heshmatzadeh Behzadi A; McDonald J
Medicine (Baltimore); 2022 Aug; 101(34):e30163. PubMed ID: 36042629
[TBL] [Abstract][Full Text] [Related]
3. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
4. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
5. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
6. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Weberling LD; Kieslich PJ; Hepp J; Kickingereder P; Wick W; Schlemmer HP; Bendszus M
Invest Radiol; 2016 Nov; 51(11):683-690. PubMed ID: 27495187
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic efficacy and safety of gadoteridol compared to gadobutrol and gadoteric acid in a large sample of CNS MRI studies at 1.5T.
Del Poggio A; Anello G; Calloni SF; Vezzulli P; Pereira C; Iadanza A; Falini A; Anzalone N
J Neuroradiol; 2022 Jan; 49(1):73-79. PubMed ID: 32603767
[TBL] [Abstract][Full Text] [Related]
8. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
Braun J; Busse R; Darmon-Kern E; Heine O; Auer J; Meyl T; Maurer M; Hamm B; de Bucourt M
Acta Radiol; 2020 Jul; 61(7):910-920. PubMed ID: 31739672
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
11. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
12. Gadolinium Deposition in the Brain in a Large Animal Model: Comparison of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Richter H; Fingerhut S; Martin LF; Xia A; Henze N; Paulus W; Sperling M; Karst U; Jeibmann A
Invest Radiol; 2019 Sep; 54(9):531-536. PubMed ID: 31261291
[TBL] [Abstract][Full Text] [Related]
13. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
14. The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study.
Moon WJ; Cho YA; Hahn S; Son HM; Woo SK; Lee YH
Contrast Media Mol Imaging; 2021; 2021():4764348. PubMed ID: 34803545
[TBL] [Abstract][Full Text] [Related]
15. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
Hieronim DE; Kanal E; Swanson DP
Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
[TBL] [Abstract][Full Text] [Related]
16. Worldwide clinical safety assessment of gadoteridol injection: an update.
Runge VM; Parker JR
Eur Radiol; 1997; 7 Suppl 5():243-5. PubMed ID: 9370551
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.
Tibussek D; Rademacher C; Caspers J; Turowski B; Schaper J; Antoch G; Klee D
Radiology; 2017 Oct; 285(1):223-230. PubMed ID: 28640695
[TBL] [Abstract][Full Text] [Related]
18. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
[TBL] [Abstract][Full Text] [Related]
20. Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.
Shahid I; Joseph A; Lancelot E
Invest Radiol; 2022 Oct; 57(10):664-673. PubMed ID: 35471204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
